AT TRUDEAU INSTITUTE, the story of 2020 is of SARS-CoV-2—the virus that causes COVID-19.

But that was just half of it.

Because even when we launched an unprecedented, breakneck-speed effort to study and treat COVID, we maintained all our other work. (Despite relocating our research teams throughout the facility after enacting our pandemic protocol, to ensure labs could stay open even if a team member became infected.)

That meant we continued seeking treatments for persistent tuberculosis. We also maintained our research to advance an effective vaccine to protect pregnant women from the Zika virus, and we ramped up our newest anti-viral platform to enable the next phase of our work on tick-borne illnesses, such as Powassan virus.

It was COVID, though, that dominated the headlines. And our three-pronged approach to that challenge is emblematic of the newest version of Trudeau—or Trudeau 3.0, as we call it.

• **Infectious disease research.** We leverage our expertise in immunology, virology and microbiology to convert advances in the lab into innovative therapies and vaccines. Even successful vaccines won’t bring this work to a close. When SARS CoV-2 brought the world to a halt, we shifted the work of one of our newest principal investigators—who brought years of experience working on viral diseases such as Ebola—to cover that as well, incorporating our expertise in computational chemogenomics to identify promising drug candidates. COVID outbreaks are likely to be with us for years to come.

• **Biomedical research operations.** Trudeau’s small size belies our capabilities. Increasingly, we are sharing our skills with world-renowned organizations that see us as a reliable, trusted partner on advanced endeavors. In this role, we carry out specialized testing and other studies for pharmaceutical companies, research institutes and other organizations. Since the beginning of COVID-19, we’ve worked with partners in an intense surge leveraging our expertise on preclinical studies on compounds and antibodies meant to treat the virus. In many cases, our COVID-19 work grew from already-established relationships with these partners.

• **Front-line efforts.** For many years, the groundbreaking research done at Trudeau has been known globally, in the science community—but often not in our own backyard. With COVID, that changed overnight. First, we began sterilizing masks for reuse by the first responders at Adirondack Health; shortly after, we began producing liquid needed to conduct COVID-19 tests. And then, in an unprecedented effort, we worked with Adirondack Health to open a regional testing lab in Saranac Lake. These partnerships harken back to our earliest days, when Edward Livingston Trudeau himself practiced medicine in our community.

Of all the factors that have helped this new, sustainable vision of Trudeau take root, the most important is holding this book: You. Your steadfast support has carried us to this day. As you read the stories on the coming pages, we hope you’ll share our pride in the Trudeau of the present—and the Trudeau yet to come.
TODAY’S TRUDEAU

Trudeau’s strength has always been an ability to get things done. And we’re needed more than ever. Today, we conduct bold in-house research while helping select partners achieve their goals.

When you spend countless hours in the laboratory, running test after test, mastering precise tools and poring over endless data sets, it can be easy to sometimes overlook the most important factor in achieving great science: People.

I could not be prouder of what our people accomplished in 2020.

Facing an unprecedented worldwide challenge, it would have been entirely understandable for our research teams to retreat into their own projects and leave work on SARS-CoV-2—the virus behind COVID-19—to other, larger organizations. Many of our labs are newly established, with their work hardly begun.

But our Trudeau team collectively joined to say: These are times that demand Trudeau. We can make a difference.

Trudeau has been a light through some of the greatest public health problems of the past century. We are not the same organization today that we were 50 years ago, or even 10. But acting boldly is in our DNA; it’s part of what I call the Trudeau spirit. How could we not enter this fray?

In introducing people to Trudeau, I often say the organization they see today is Trudeau 3.0. Trudeau 1.0 was our original incarnation, as a sanitarium and home for tuberculosis research. As Trudeau 2.0, we worked on our own to study the immune system and combat infectious disease.

Today, as Trudeau 3.0, we remain a place where great science can be completed without distraction. Our three newest principal investigators, each of whom are featured in this report, can attest to that: Dr. Priya Luthra (coronavirus and ticks); Dr. Deb Brown (vaccine platforms, and our education leader); and Dr. Paras Jain (who becomes the third member of our core TB team, fully enabling our unique platform to discover superior shorter-course TB medicines.) Each of these three lead labs that are Trudeau’s priority focus areas. At the same time, we’ve become a vital resource to help other institutions carry out their own translational science focused against infectious diseases, using our remarkable knowhow and special lab facilities.

These partnerships are integral to ensuring Trudeau remains a vital scientific enterprise. Our friend (and Trudeau Fellow) Dr. Stephen Thomas, chief of infectious diseases at SUNY Upstate, describes us to others as follows:

“They are not government, they are not pharma, and they are not academic. But they have the best elements from each. They are mission-driven, but they don’t answer to shareholders. They can move faster than academia and the government. And they have resources like all of those entities.”

As you read this report, and you see the value of the work done by our people, I hope you’ll also recognize the contributions of another invaluable group: Our supporters. We are deeply grateful for all you’ve done to ensure Trudeau remains vital and relevant.

Sincerely,

Atsuo Kuki, Ph.D.
President and Director

To Our Friends:

Our research benefits the world, but the Adirondacks are our home. When COVID-19 struck, we worked directly with local health-care partners to ease the threat.

N-95 Masks sterilized for Adirondack Health: 9,450

2019-2020
Growth: 2.6X

Principal Investigators hired in 2020: 2 (Total: 8)

We continue to pursue breakthroughs in tuberculosis, tick-borne diseases, COVID-19 and other threats.
In a year when science commanded the attention of the world, we were reminded every day: No advances are possible without the people who have dedicated their lives to the quest for better health. At Trudeau, the story is no different. All our work, not just on COVID-19 but tuberculosis, tick-borne illnesses, Zika and other diseases, revolves around the men and women who work here.

With that in mind, we asked some of our researchers, technicians and staff to explain why, more than 60 years after Frank Trudeau established this institute, not just why the work they do here today is as important as ever, but also what it was like to be part of a singular moment in history, when much of the world’s scientific firepower was trained on the same target.

“...In my very first week, we went into lockdown. Others had to stay home, but we got the COVID lab going. New labs are challenging enough; we were working with a pathogen nobody knew about. But we have the facilities, and the people, to handle it. Trudeau may be small, but we’re like a special-forces team. If given a task, we can do it.”
Every spring, Clarkson University students come here for a semester. You don’t get this kind of experience as an undergraduate anywhere else; ‘I was trained at the Trudeau Institute’ carries a lot of weight. But it’s also important for the community. Whenever we show how vaccines and infectious diseases work, and why we’re wearing masks, that contributes to science literacy. These kids go on to educate their family, peers, and everyone they interact with.

Some battles can only be won when we work together to find solutions. My personal passion is about researching efficient ways to eliminate Mycobacterium tuberculosis. At Trudeau, this work is not just about me—it is about what we can do collectively to eradicate TB.
“My work helps researchers see how viruses infect cells, or how therapeutic candidates might treat infection. Often, we’re working with viruses that have been around for hundreds and hundreds of years. When you work on a new problem like COVID, there’s a rush to figure out what’s going on. It’s exciting: For people who are science geeks, it’s really interesting. And it’s a little bit frantic.”

“COVID proved we could come together as a team and say: We’re going to contribute. We’ve had a lot of it-takes-a-village days. And some days are really long. Because once you go in the lab and put on all that garb, you’re not coming out—PPE shortages are real. You have to communicate well in order to work safely. At the end of the day, it’s pretty gratifying.”
A YEAR FOR THE AGES

When COVID-19 struck, Trudeau Institute was like many other organizations: Scrambling to ensure it could simply operate. But unlike most other organizations, Trudeau has staked its very existence on easing the scourge of disease. It wasn’t long before the Institute made the commitment to join the worldwide fight against COVID—first by helping Adirondack Health, the region’s leading healthcare institution, protect the community. And then by throwing its research might into the effort.

In their own words, Trudeau President and Director Atsuo Kuki, Trudeau Chair Dorothy Federman, and Adirondack Health CEO Sylvia Getman reflect about the uncertainty of the earliest days of the pandemic, the partnership that resulted and what this challenge augurs for Trudeau’s future.

In early March 2020, Trudeau activated its pandemic response plan, launching a fast-moving chain of events.

Atsuo Kuki: We put into place protective measures to keep our staff as safe as possible, as we are experts in both sterilization techniques and personal protective equipment. It wasn’t long before we realized we could help frontline health workers. Two early creative breakthroughs came from our technical staff. They suggested using rigorous sterilization methods for the hospital’s N-95 masks, and producing the testing liquid needed by the hospital for COVID-19 tests. I knew these contributions were the right thing to do. But while normally we do things very methodically, now we were going to do things very quickly. The impact of supplying thousands of vials of COVID testing liquid was felt swiftly, as the uninterrupted testing helped the North Country demonstrate required criteria for regional reopening.

While this kind of clinical partnership was unlike anything Trudeau has done in recent years, nobody hesitated.

Dorothy Federman: This crisis matched our obvious ability to make a difference in a moment where people wanted to be helpful and useful. It utterly matched the needs of the community. I mean, what luck for the region! We’re not clinical, and it’s not our mission. But that’s part of our legacy. Edward Livingston Trudeau and Frank Trudeau were medical doctors, and our community is integral to what we are. We’re not just high on the hill.

Adirondack Health knew as early as February 2020 that restocking critical supplies would become difficult; soon after, those prospects grew even darker.

Sylvia Getman: It became clear, by the third week in March, that we needed to identify new sterilization measures for masks. We thought such a process would involve UV light. But we learned from our counterparts at Trudeau they had the capability to use vaporized hydrogen peroxide to reprocess larger quantities, with shorter turnaround times.

My primary responsibility as Adirondack Health’s president & CEO is to do everything possible to keep our employees and patients safe. In those early, dark days, we had no way of knowing if “everything possible” was going to be sufficient. The day that first batch of sanitized masks came back from Trudeau, there was almost an audible sigh of relief across the organization.

That initial assistance led to an even bigger project: Working with Adirondack Health to raise hundreds of thousands of dollars and install COVID-19 testing equipment at the hospital.

AK: I had the sense that Trudeau could do more, and that Saranac Lake could do more. So I started to call people in my network. I asked the question: What is the biggest contribution that will change the course of our ability to survive this pandemic? And all of those contributions were front-line, real-time contributions.

In October, Trudeau and Adirondack Health opened a regional COVID testing lab. While it’s staffed by Adirondack Health personnel, Trudeau scientists will also be able to scout for future viral threats long after the COVID-19 crisis passes.

DF: Our newest machine is open-channel, which means you can develop new tests on it. If a future virologist at Trudeau has samples that need that kind of machine, it can be an asset to recruit a person, to look for funding, to help biomedical science. That machine isn’t just for clinical medicine.

Trudeau researchers have ramped up their efforts to study how COVID-19 works, built a platform for a targeted search for new anti-viral medicines, and have partnered with other institutions that benefit from Trudeau’s specialized teams to accelerate projects to prevent and treat COVID-19.

AK: The most important reflection is that all of this capability, our infrastructure, is only as good as our teams. And the teams really stepped up. People in the community should be really proud of the staff; all of this is only made possible because of their enormous dedication. This was very hard work to do—the intensity and speed of bringing up a very large number of research protocols all at once.

SG: I think it was comforting for community members to know that at Adirondack Health, and at Trudeau Institute, in those big brick buildings on the edges of town, there were world-class professionals working around the clock to solve problems and keep everyone safe. And there still are.

Once this crisis passes, what will be next?

SG: There will be many more opportunities to align bioscience and healthcare delivery. While it is somewhat rare to see those opportunities present in a location as rural as ours, it is exciting, and incredibly beneficial to the North Country.

DF: This will be the first pandemic of the 21st century. There will be more. There’s world travel, and climate change, and a lack of trust in public health. But for Trudeau, I think our approach to COVID-19 will mark an inflection point. I think this could mark the beginning of Trudeau being really secure, and sustainable, and special.

AK: It’s definitely the beginning of new opportunities. The Trudeau enterprise is very naturally suited to leadership contributions that impact the community. Our enterprise is always greater than the bricks and mortar. The Trudeau spirit, with both the scientific and regional purpose, endures.

Dorothy Federman, M.D., chair, Trudeau’s Board of Trustees

Dorothy Federman, M.D., chair, Trudeau’s Board of Trustees
As lead investigator, Thomas helped Pfizer prepare trial data for regulatory agencies, which gave an emergency use authorization to the vaccine late last year. His experience working on a once-in-a-lifetime pandemic crystallized a couple of basic concepts for him:

Being prepared to pivot to the next big thing takes a lavish investment in people and infrastructure. And the speed of working on a global challenge like COVID is unlike anything he’s ever encountered.

Trudeau, he said, excels at both. “They’ve got the fancy cameras and microscopes and labs,” Thomas said. “But the most important thing, obviously, is the people that they’re investing in.”

Thomas is working on Zika research with Trudeau. He is also helping to plan Trudeau’s second Global Health Summit planned for the fall, an event that will bring together some of the world’s most notable scientists and clinicians. He tells potential partners that the institute, unburdened by much of the red tape that plagues government and academia, has made the investments necessary to focus on tackling big problems when they arise. And that’s never been clearer than now.

“Trudeau said, we’re a boutique group in the Adirondacks, and this is a huge pandemic, but we’re jumping in the pool with everybody else and we’re going to do our part,” Thomas said. “To me, that speaks volumes. There’s no problem too big or environment too competitive that they’re not willing to jump in and participate. That’s huge.”

Read the “Disease X” paper here: https://pubmed.ncbi.nlm.nih.gov/31500964/
2020 CONTRIBUTIONS

DONORS

Leadership Circle ($100,000 and up)
The Ambrose Monell Foundation

Governor’s Circle ($50,000 to $99,999)
Anonymous
Cloudsplitter Foundation
The McCutchen Foundation

Second-Century Circle ($20,000 to $49,999)
The Donald C. McGraw Foundation
Fund and Robin and Buzz McGraw
F.M. Kirby Foundation, Inc.
Mclanahan Family Fund at
Adirondack Foundation
Dr. and Mrs. Michael J. Parker
Mr. and Mrs. Garry Trudeau
The Estate of Ursula Trudeau
Henry Uhlein II and Mildred A.
Uhlein Foundation

Founder’s Circle ($6,000 to $19,999)
Adirondack Foundation–Special and
Urgent Needs Fund
Mr. and Mrs. Benjamin Brewster
Mr. and Mrs. Alexander W. Dreyfoos
Drs. Jay and Dorothy Federman
Joan Grabe Family Fund at
Adirondack Foundation
John and Evelyn Trevor
Charitable Foundation
Dr. Atsuo Kuki
Mr. and Mrs. Konrad (Kip) Testwuide

President’s Circle ($3,000 to $5,999)
Adirondack Foundation at the request of
Caroline and Serge Lussi
Dr. and Mrs. James C. Frauenthal
Lake Placid Education Foundation at
Adirondack Foundation
Dr. and Mrs. Raymond N. Johnson
Mr. and Mrs. Daniel Leff
Dr. Airlie C. Lennon
Ms. Julie A. North and Mr. William V. Fogg
Dr. Lida Orzeck
Sonneborn Adirondack Fund at
Adirondack Foundation
Staritch Foundation, Inc.
Mr. and Mrs. Alexander B. Trevor
Mr. and Mrs. Roy T. Van Vleck
Dr. Tielman Van Vleck

Director’s Circle ($1,000 to $2,999)
Adele & Tom Connors Fund at
Adirondack Foundation
Bionique Testing Laboratories, Inc.
Ms. Courtney Burke
Combined Federal Campaign
Mrs. Mary Ann Casey
Sue and Herb Cohen
Mr. and Mrs. Doug Colson
Mr. and Mrs. J. Dennis Delafeld
Evergreen Fund at Adirondack Foundation
Denis Faucher
Mr. and Mrs. Henry A. Fenn, Jr.
Ms. Priscilla C. Goss
Mr. and Mrs. John Hemphill
Dr. Neil A. Holtzman
Mr. and Mrs. James Hotaling
Dr. Daniel R. Karlin
Mr. and Mrs. Andrew S. Kennedy
Krackeler Scientific, Inc.
Ms. Nancy Lester
Ms. Carol Levy
Lower Saranac Lake Shore Owners
Association
Mr. and Mrs. George G. Matthews
Mr. and Mrs. Clement McGillicuddy
Mr. and Mrs. Richard A. McGinn
Mr. and Mrs. Mauricio Pages
The Pfizer Foundation
Price Chopper Golub Foundation
Drs. Henry M. and Judith Sondheimer
Stewart’s Shops
Mr. and Mrs. Konrad Testwuide
Trevor Fund for Trudeau Institute at
Adirondack Foundation
Kiri, Mark and Mary Wilson

Sponsors ($500 to $999)
Adirondack Foundation–
Peter and Heidi Roland Family Fund
Kathy and Colt Bagley
Mr. and Mrs. Barry F. Berkov
Mr. and Mrs. Edward W. Bickford
Mr. and Mrs. Peter W. Bickford
Mr. and Mrs. William B. Biddle
Mr. and Mrs. Daniel Brody
Mrs. Edwina Corman
Mr. and Mrs. Mark Crawford
Dr. and Mrs. Edward Crum
Michael Elitzer
ExxonMobil Foundation, Inc.
The Janet Stone Jones Foundation
Mr. and Mrs. David P. Kirstein
Mr. and Mrs. Richard J. Leamer
Mr. and Mrs. Patrick R. McDonald
Dr. and Mrs. Robert J. North
Stuart S. Applebaum Giving Foundation
Ms. Michelle B. Trudeau and
Dr. Steven G. Potkin

Patrons ($250 to $499)
Mr. Aasim Azad
Mr. and Mrs. Perrin L. Babcock
Mr. and Mrs. Matthew P. Baker
Dr. and Mrs. Michael A. Bettman
Mr. and Mrs. William Chapin
Mr. and Mrs. John F. Heimerding
Mr. and Mrs. William C. Joneway
Dr. and Mrs. David A. Johnson
Dr. Alexander Maue
Mr. Peter McHugh and
Ms. Louise McNamne
Mr. Peter S. Paine Jr.
Dr. Brian A. Pollok
Mrs. Meredith M. Prime
Mr. and Mrs. Richard A. Trudeau

Supporters ($100 to $249)
Mrs. Scottie Adams
Sarah Ames
Mr. and Mrs. A. Joseph Armstrong
Mr. Richard Beamish and Ms. Rachel Rice
Mr. and Mrs. Brian W. Bliss
Ms. Patricia Tankard Brown
Dr. Kathryn Weld Brown
Mr. Benjamin L. Chapman
Mr. Stephen A. Dehond
Mr. Thomas H. Delahant
Dr. and Mrs. Vincent Fischetti
Mrs. Mabel E. Foote
Kathy and Lonnie Ford
Ms. Nancy J. Haneman
Dr. Paul J. Herrmann
Mrs. Leslie Hoopes
Mrs. Betty Hunkins
Dr. and Mrs. Christopher P. Hyson
Ms. Georgia J. Jones
Jennifer Juzaits
Mr. and Mrs. Michael Kamen
Mr. George L. Leedom
Dr. and Mrs. Woods McCallin Jr.
Mr. and Mrs. Eugene Bradley Meyer
Dr. and Mrs. Thomas Minehan
Mr. and Mrs. Don Morgan
Mr. and Mrs. Arthur G. Olver
Marijke Ornell-Cook

Friends ($25 to $99)
Adirondack Publishing Co., Inc
Mr. and Mrs. J. Ripley Allen
AmazonSmile Organization
Mr. and Mrs. Lionel Arlan
Dr. and Mrs. John Cogar
Mr. Darrell Davies
Mrs. Barbara Dwyer
Mr. George H. Earle
Ms. DeWreath Francis
Ms. Margot Gold
Mr. and Mrs. David R. Hanning
Dr. and Mrs. Richard Kasulke
Mr. Arthur Kirsch
Mr. Kevin J. Laplante
Dr. and Mrs. Albert A. Lewis
Mr. and Mrs. Gerald Matacotta
Dr. and Mrs. Lawrence H. Poole
Ms. Leslie A. Richter
Mr. and Mrs. Robert Roppolo
Mr. and Mrs. Tom Stanyon
Mr. and Mrs. Robert E. Sweet
Margaret Tissot
Mr. and Mrs. Thomas M. Willis Jr.

TRIBUTES
Dorothy Federman
Sara Ames
Mr. Lionel Arlan
Mr. and Mrs. David Kirstein
Dr. Lida Orzeck
Mr. and Mrs. Christopher Wood

Patricia Tsien
Mr. and Mrs. Robert R. Zahm

Mr. Benjamin Brewster
Mr. R.V. Whisnand

MEMORIALS
The Bickford Family Fund
Mr. and Mrs. Edward W. Bickford
Mr. and Mrs. Peter W. Bickford
Mary Ann Casey
W. Neil Thomas III

U.S. Sen. Kirsten Gillibrand visited Trudeau in July 2020, taking special interest in our ongoing efforts to fight COVID-19. Following a tour with Trudeau President Atsuo Kuki, Sen. Gillibrand delivered remarks to a group of supporters and staff. “They’re doing fundamental research on COVID. And if we want to have vaccinations, cures and other treatments, the work they do here is essential,” she said.
Although the greatest possible care has been taken preparing donor recognition, inaccuracies may occur. If errors are noted, please accept our apology and share corrections.

Regional Testing Lab Donors

Our partnership with Adirondack Health to combat COVID-19 on a local level was a bright spot in a challenging year. These generous donors helped establish the Stoltz Infectious Disease Testing Center at the Adirondack Medical Center, which allows the hospital to process COVID-19 tests swiftly, on site, without relying on overwhelmed and distant labs. We’re grateful for their support.

Adirondack Foundation—ACK Lussi Fund
Adirondack Foundation—Adele and Tom Connors Fund
Adirondack Foundation at the request of Caroline and Serge Lussi
Adirondack Foundation—McLanahan Family Fund
Adirondack Foundation—Mirror Lake Inn Charitable Fund
Adirondack Foundation—Peter and Heidi Roland Family Fund
Adirondack Foundation—Special and Urgent Needs Fund
Sara Ames in honor of Dorothy Federman
Stuart S. Applebaum Giving Foundation
Kathy and Colt Bagley
Leslie Becker
Ellen and Michael Bettmann
Heather and David Burmsted
Sue and Herb Cohen
Kathleen and Doug Colson
Marjke Ormel-Cook and George Cook, M.D.
Jeannie Cross and Thomas Woodman
David McGraw Foundation
The Donald C. McGraw Foundation
Fund and Robin and Buzz McGraw
Darlene and Patrick Donnelly
Michael Elitzer
Essex County
Denis Faucher
Dorothy and Jay Federman
Kathy and Lonnie Ford
Tina and Kevin Fountain
Barbara and Michael Franklin
Sylvia and Bill Getman
Priscilla Goss
Joan and William Grabe
Nancy Hanerman
Hannah Hanford and JD Duval
Sandra Hildreth
Jennifer Juzaitis
Stephanie and Barry Kilbourne, M.D.
Dr. Atsuo Kuki
Arlie Lennon
Lower Saranac Lake Shore Owners Association
Marie and George McBride
Thomas McGowan IV and Nicolle McGowan, M.D.
John Norton
Brad Parker
Lauren and John Roth
Laura and Doug Rumbough
Betsy and Dan Senkowski
Rich Shapiro & Lindy Ellis
Staritch Foundation
The Stoltz Family
Deacon Joseph and Beryl Szwed
Julie and Kip Testwuide
Margaret Tissot
Ulilhein Foundation
Elizabeth and Tom Vales
Albert Wheeler
Kim, Mark and Mary Wilson in memory of Dr. Donald Kennedy
Torrance York and Greg Walters

THE FOUNDERS’ SOCIETY

To recognize our generous donors who have made a commitment to the future of the Trudeau Institute through their estate planning, we have established The Founders’ Society. This vital component of the Institute’s advancement programs is our primary mechanism for building the endowment.

The Trudeau Institute gratefully acknowledges its supporters who, through their thoughtful planned gifts, enable our research to continue into the future. If you would like to include the Institute in your future estate plans, or have already, please notify us so that we ensure your wishes are met and acknowledged properly.

Members
Richard Baker*
James J. Barba
Ann Bickford*
Diana Bourke
Benjamin Brewster
Josephine T. Brune*
Isabel Collier Read*
Edwina De Mattos Cormier
Alexander Dreyfoos
Mildred Duncan*
Alfred Edwards Schlesinger*
Dorothy Swern Federman, M.D.
Jay Federman, M.D.
Henry A. Fenn, Jr.
Ronald H. Goldfarb, Ph.D.
Priscilla Goss
George T. Hartt*

*Gift realized

We gratefully acknowledge all the federal employees who contributed through the Combined Federal Campaign to the Cancer and Aging Research Program at the Trudeau Institute.

The Trudeau Institute acknowledges the National Institutes of Health for its vital ongoing support. As the nation’s primary federal agency for conducting and supporting medical research, the NIH shares the Institute’s mission to make medical discoveries that improve health and save lives.
STAFF

SENIOR MANAGEMENT
Atsuo Kuki, Ph.D.
President and Director
William B. Chapin, M.B.A.
Chief Administrative Officer/Controller

TRudeau PRinCIpAL iNVESTIGATORS
Marcia A. Blackman, Ph.D.
Influenza, Aging, Ferret & Vaccine Technology. TRN Senior Principal Immunologist and Leader, Viral Immunity Program.
Deborah Brown, Ph.D.
Vaccine Translational Science. Manager, Joint Educational Programs.

Paras Jain, Ph.D.
Molecular Geneticist
In-Jeong Kim, Ph.D.
Vaccine Translational Science. TRN Senior Immunologist and Leader, Flavivirus Research Platform.
Priya Luthra, Ph.D.
Viral Diseases Research & Translational Science

William W. Reiley, Ph.D.
Chief Scientific Officer, TICRO BioServices. Member, TB and Influenza Program.
Felix Sheinerman, Ph.D.
Head of Chemogenomics
Brian Weintrick, Ph.D.
TR R&D Program, Lead Investigator

POSTDOCTORAL FELLOWS
Gaelle Guiwet, Ph.D.

SENIOR RESEARCH TECHNICIANS
Tres S. Cookenham III, A.A.S.
Debra K. Duso, A.A.S.
Kathleen G. Lanzer, B.S.
TRN Scientific Coordinator
Paula A. Lanther, A.A.S.
Alan D. Roberts, B.S.
Frank M. Szaba, B.S., B.A.
Michael P. Tighe, A.A.S.

Head, Trudeau Imaging Core

ADJUNCT PRINCIPAL INVESTIGATORS
Ilia Ichetovkin, Ph.D.
High-complexity infectious diseases and molecular oncology clinical diagnostics (CLIA). Highland Park, N.J.

Saravanan Thangamani, Ph.D.
SUNY Empire Innovation Professor, SUNY Upstate Medical University. Director, SUNY Center for Environmental Health and Medicine. Director, Vector Biology Laboratories. Syracuse.

Jerrold Ward, DVM, Ph.D.
Chief, Infectious Disease Pathogenesis, Comparative Medicine Branch, NIAID, NIH (retired). Distinguished Member, American College of Veterinary Pathologists, Montgomery Village, Md.

RESEARCH TECHNICIANS
Derek Bernacki
FACS Coordinator
Madeline Clark, M.S.
Laura Cole, B.S.
Timothy Low-Beer, B.S.
Lea Maney, B.S.
Stanzin Idga, B.S.
Lawrence W. Kummer, B.S.
Tricia Lang, B.S.
Shania Muncil, B.S.
Natalie Oberding, M.A.P.S.
Kelsey Travis, B.S.

LABORATORY OPERATIONS
Jody L. Hart, B.S.
Manager, Technical Services
Jon M. Law, Sr.
Manager, Facilities
Lynn M. Ryan, B.A.
Manager, Occupational Health & Safety
Amanda A. Schneck, B.A.
Manager, Animal Facilities

ANIMAL TECHNICAL SERVICES
Jenna Friers, B.S.
Animal Health/Veterinary Technician
Jody L. Hart, B.S.
Manager, Animal Technical Services

ANIMAL HUSBANDRY
Nicole Beaudoin
Animal Care Technician 2
Jeremy Ellis, B.S.
Animal Care Technician 1
Jonathan A. Lauber
Animal Care Technician 2/ Sterilization Technician
Jill E. Miller, A.A.S.
Animal Care Technician 2
Amanda A. Schneck, B.A.
Manager, Animal Facilities

Toni F. Vincent
Animal Facilities Clerk
William T. White
Animal Care Technician 2

HOUSEKEEPING
Timothy T. Harrigan, A.A.S.
Bill Jo Symonds
Housekeeping Supervisor
Kerry White

MAINTENANCE
David L. Benham
Maintenance Carpenter
Shawn R. Boyer
Boiler Operator
Michael Carter
Building Support Technician
Jon M. Law, Sr.
Manager, Facilities
Chad Mason
Electrician
Stephen Smith, B.A.
Equipment/Grounds Technician

ADMINISTRATION
Perrin Babcock, M.A.
Manager, Development Office
Charles T. Billingsley, B.S.
Manager, Computer Services

DONOR PROFILE
TO MANY PEOPLE, TUBERCULOSIS is an abstraction—a disease in America’s past, or something that affects people elsewhere. To Priscilla Goss, it’s an elemental part of her story. And it kindled decades of support of the Trudeau Institute.

Her father, Louis Mackay, came to Saranac Lake in 1930 to rehabilitate from the disease. Early on in his time here, he met Helen Jensen, a young woman from New Jersey visiting a mutual friend. They fell in love but courted from afar, because it took her two days to drive north in her Ford Model A.

Mackay stayed in a succession of cure cottages. (“To the day he died, he slept on an open-air porch at our house,” Goss said.) They married shortly after he finally recovered, in 1936. Priscilla, named for that mutual friend, was born in 1943.

In 1991, Goss received a surprise bequest from a longtime family friend who had met her parents in Saranac Lake. She knew exactly how to honor them: By passing it to Trudeau. “I came to see Frank Trudeau himself,” she said.

“We had tea in the library and I gave him the check.”

And she hasn’t stopped giving, because she sees how the institute improves the lives of others in the same way that her father benefited from E.L. Trudeau’s life’s work.

She sees COVID as a stark reminder of the need for dedicated researchers to face down a constellation of threats: Lyme disease, Zika, Powassan. “The Institute studies so many different aspects of infectious disease, and all of it is so important for the world,” said Goss, who moved to the Adirondacks with her late husband in 2002 and remains here today. “This is the future of health. I want to be a part of that.”
STATEMENT OF FINANCIAL POSITION
FISCAL YEARS ENDED DECEMBER 31

ASSETS

<table>
<thead>
<tr>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$900,004</td>
</tr>
<tr>
<td>Grants receivable</td>
<td>1,510,786</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>12,191,384</td>
</tr>
<tr>
<td>Other assets</td>
<td>250,549</td>
</tr>
<tr>
<td>Property, plant and equipment, net</td>
<td>14,050,607</td>
</tr>
<tr>
<td>Funds held in trusts</td>
<td>3,989,250</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>32,892,580</strong></td>
</tr>
</tbody>
</table>

LIABILITIES

<table>
<thead>
<tr>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$343,223</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>22,156</td>
</tr>
<tr>
<td>Capital lease obligation</td>
<td>—</td>
</tr>
<tr>
<td>Loan payable</td>
<td>—</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>365,379</strong></td>
</tr>
</tbody>
</table>

NET ASSETS

Unrestricted:
- Available for operations | 21,584,832 | 24,782,161 |
- Internally designated/Edward C. Brewster Fund | 4,000,000 | 4,000,000 |
- **Total unrestricted** | 25,584,832 | 28,782,161 |
- Temporarily restricted | 404,192 | 1,050,625 |
- Permanently restricted:
  - Endowments | 1,444,261 | 1,444,261 |
  - Funds held in trusts | 3,989,250 | 3,668,254 |
  - Francis B. Trudeau Chair | 1,104,666 | 1,104,666 |
- **Total permanently restricted** | 6,538,177 | 6,217,181 |
- **TOTAL NET ASSETS** | **32,527,201** | **36,049,967** |
- **TOTAL LIABILITIES AND NET ASSETS** | **32,892,580** | **36,605,912** |